Payment overview · 2025
General Payments
$1,056.18
33 reported records · 14 companies
Healthcare provider profile · identity verified
Abdul R Moosa, MD
Allopathic & Osteopathic Physicians|Family Medicine · WEBSTER, TX · NPI 1871555052
Verified facts
What the public records show
CMS Open Payments records show Abdul R Moosa, MD received $1,056.18 in general payments during 2025 across 33 reported records.
MIMEDX Group, Inc. accounted for 23.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $247.06 | 23.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $179.10 | 17.0% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $121.86 | 11.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $117.28 | 11.1% | 1 | 2025 |
| ETS Wound Care LLC | Unresolved — no canonical attribution shown | $91.15 | 8.6% | 7 | 2025 |
| Aroa Biosurgery Incorporated | Unresolved — no canonical attribution shown | $88.96 | 8.4% | 3 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $54.81 | 5.2% | 2 | 2025 |
| Solventum Corporation | Unresolved — no canonical attribution shown | $35.05 | 3.3% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $28.78 | 2.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $22.60 | 2.1% | 1 | 2025 |
| Reprise Biomedical, Inc. | Unresolved — no canonical attribution shown | $19.74 | 1.9% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.86 | 1.6% | 1 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $16.64 | 1.6% | 1 | 2025 |
| Kerecis Limited | Unresolved — no canonical attribution shown | $16.29 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,056.18 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DALVANCE Normalized: dalvance |
Drug | ABBVIE INC. | $179.10 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $121.86 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $117.28 | 1 | 2025 |
Source payment records
|
|||||
| MIRRAGEN ADVANCED WOUND MATRIX Normalized: mirragen advanced wound matrix |
Device | ETS Wound Care LLC | $91.15 | 7 | 2025 |
Source payment records
|
|||||
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $54.81 | 2 | 2025 |
Source payment records
|
|||||
| ACTIV.A.C. Normalized: activ a c |
Device | Solventum Corporation | $35.05 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $28.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| Miro3D Normalized: miro3d |
Device | Reprise Biomedical, Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.86 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $16.29 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Mupirocin | Mupirocin | 158 | 76 |
| Gentamicin Sulfate | Gentamicin Sulfate | 66 | 32 |
| Atorvastatin Calcium | Atorvastatin Calcium | 51 | 22 |
| Nystatin | Nystatin | 50 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 45 | 22 |
| Tramadol Hcl | Tramadol Hcl | 45 | 14 |
| Pantoprazole Sodium | Pantoprazole Sodium | 35 | 15 |
| Losartan Potassium | Losartan Potassium | 34 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 34 | 14 |
| Amlodipine Besylate | Amlodipine Besylate | 33 | 15 |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 16 |
| Gabapentin | Gabapentin | 28 | 14 |
| Levofloxacin | Levofloxacin | 26 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 25 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Ozempic | Semaglutide | 24 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 23 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 23 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 21 | 12 |
| Lisinopril | Lisinopril | 20 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Clonazepam | Clonazepam | 19 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Metformin Hcl | Metformin Hcl | 16 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,056.18 · 33 records | MIMEDX Group, Inc. | ACTIV.A.C., Cologuard Collection Kit, DALVANCE, KRYSTEXXA, Kerecis GraftGuide, Kerecis SurgiClose, LYMPHA PRESS OPTIMAL PLUS(US) BT, MIRRAGEN ADVANCED WOUND MATRIX, Miro3D, NUZYRA, Ozempic, PCD-51 731A (US) - White, PCD-52 737A (US) White, RENASYS TOUCH, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error